603 Page 1 22-Sep-2026 To Company Name/SchemeACN/ARSN1. Details of substantial holder (1)NameACN/ARSN (if applicable)The holder became a substantial holder on18/09/20262. Details of voting powerThe total number of votes attached to all the voting shares in the company or voting interests in the...
Becoming a substantial holder
Filed with ASX ·
6ix hasn’t read this filing yet.
Clarity Pharmaceuticals Ltd. on 6ix
Earlier from Clarity Pharmaceuticals
- Date of Annual General Meeting 25 November 2026
- Preliminary Final Report
- Ceasing to be a substantial holder
- Bioshares Biotech Summit Presentation
- Clarity Pharmaceuticals Announces SECuRE Trial Update on 8 GBq 67Cu-SAR-bisPSMA dose level with two additional complete responses
Later from Clarity Pharmaceuticals
- Annual Report to shareholders
- Appendix 4G
- Corporate governance statement
- SECuRE update
- SAR-bisPSMA Presentation - Drug & Device Conference
